 | Up a level |
2020
Zinzani, Pier Luigi, Chen, Robert, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John 
ORCID: 0000-0001-7898-2786, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Nahar, Akash, Balakumaran, Arun and Moskowitz, Craig H.
(2020).
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis.
Leuk. Lymphoma, 61 (4).
S. 950 - 955.
ABINGDON:
TAYLOR & FRANCIS LTD.
ISSN 1029-2403
2019
Chen, Robert, Zinzani, Pier Luigi, Lee, Hun Ju, Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Lin, Jianxin, Kim, Eunhee, Nahar, Akash, Balakumaran, Arun and Moskowitz, Craig H. (2019). Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood, 134 (14). S. 1144 - 1154. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
von Tresckow, Bastian, Fanale, Michelle, Ardeshna, Kirit M., Chen, Robert, Meissner, Julia, Morschhauser, Franck, Moskowitz, Craig, Zinzani, Pier Luigi, Giezek, Hilde, Balakumaran, Arun, Vo, Thao T., Raut, Monika and Brice, Pauline (2019). Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Leuk. Lymphoma, 60 (11). S. 2705 - 2712. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403
2017
Chen, Robert, Zinzani, Pier Luigi, Fanale, Michelle A., Armand, Philippe, Johnson, Nathalie A., Brice, Pauline, Radford, John, Ribrag, Vincent, Molin, Daniel, Vassilakopoulos, Theodoros P., Tomita, Akihiro, von Tresckow, Bastian, Shipp, Margaret A., Zhang, Yinghua, Ricart, Alejandro D., Balakumaran, Arun and Moskowitz, Craig H. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. J. Clin. Oncol., 35 (19). S. 2125 - 2135. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
2016
Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham and Younes, Anas (2016). Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood, 128 (12). S. 1562 - 1567. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
2015
Chen, Robert, Gopal, Ajay K., Smith, Scott E., Ansell, Stephen, Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Huebner, Dirk, Fong, Abraham and Younes, Anas (2015). Five-Year Survival Data Demonstrating Durable Responses from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L. and Younes, Anas (2015). Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 125 (8). S. 1236 - 1244. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Gopal, Ajay K., Chen, Robert, Smith, Scott E., Ansell, Stephen M., Rosenblatt, Joseph D., Savage, Kerry J., Connors, Joseph M., Engert, Andreas, Larsen, Emily K., Chi, Xuedong, Sievers, Eric L. and Younes, Anas (2015). Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Blood, 125 (8). S. 1236 - 1244. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020